Eli Lilly & Co. (LLY)
1157.93
-16.68
(-1.42%)
USD |
NYSE |
Aug 31, 16:00
1161.07
+3.14
(+0.27%)
After-Hours: 20:00
Eli Lilly Cash from Operations (TTM) : 28.08B for June 30, 2026
Cash from Operations (TTM) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Cash from Operations (TTM) Data
| Date | Value |
|---|---|
| June 30, 2026 | 28.08B |
| March 31, 2026 | 20.48B |
| December 31, 2025 | 16.81B |
| September 30, 2025 | 16.06B |
| June 30, 2025 | 10.94B |
| March 31, 2025 | 9.318B |
| December 31, 2024 | 8.818B |
| September 30, 2024 | 6.032B |
| June 30, 2024 | 4.510B |
| March 31, 2024 | 3.676B |
| December 31, 2023 | 4.240B |
| September 30, 2023 | 6.132B |
| June 30, 2023 | 6.127B |
| March 31, 2023 | 6.316B |
| December 31, 2022 | 7.084B |
| September 30, 2022 | 7.661B |
| June 30, 2022 | 7.108B |
| March 31, 2022 | 8.062B |
| December 31, 2021 | 7.261B |
| September 30, 2021 | 6.919B |
| June 30, 2021 | 7.095B |
| March 31, 2021 | 7.815B |
| December 31, 2020 | 6.500B |
| September 30, 2020 | 6.648B |
| June 30, 2020 | 6.352B |
| Date | Value |
|---|---|
| March 31, 2020 | 4.908B |
| December 31, 2019 | 4.837B |
| September 30, 2019 | 4.322B |
| June 30, 2019 | 4.933B |
| March 31, 2019 | 5.399B |
| December 31, 2018 | 5.524B |
| September 30, 2018 | 5.819B |
| June 30, 2018 | 5.579B |
| March 31, 2018 | 5.712B |
| December 31, 2017 | 5.616B |
| September 30, 2017 | 5.989B |
| June 30, 2017 | 5.767B |
| March 31, 2017 | 5.518B |
| December 31, 2016 | 4.851B |
| September 30, 2016 | 3.538B |
| June 30, 2016 | 2.984B |
| March 31, 2016 | 2.531B |
| December 31, 2015 | 2.773B |
| September 30, 2015 | 3.318B |
| June 30, 2015 | 3.905B |
| March 31, 2015 | 4.01B |
| December 31, 2014 | 4.367B |
| September 30, 2014 | 4.744B |
| June 30, 2014 | 5.045B |
| March 31, 2014 | 5.628B |
Cash From Operations Definition
Represents the net cash flow from the company's business operations.
Cash from Operations (TTM) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Cash from Operations (TTM) Benchmarks
| Johnson & Johnson | 27.61B |
| Merck & Co., Inc. | 19.97B |
| Pfizer Inc. | 13.40B |
| Bristol Myers Squibb Co. | 12.78B |
| Atai Beckley, Inc. | -128.93M |